India’s drug regulator has put the pharmaceutical supply chain on notice. A CDSCO communication dated 27 October 2026 directs State and Union Territory Drug Controllers to ensure that no batch of a specified high-risk pharmaceutical-grade solvent leaves a factory without being registered on the ONDLS portal and cleared with a system-generated No Objection Certificate (NOC). The order covers ten solvent and excipient groups used in oral liquids, cough syrups, tablets and injectables — and on 3 November 2026 the pharmaceutical industry asked the regulator to clarify whether the requirement extends to export-oriented manufacturers as well.
⚖️ What the 27 October 2026 CDSCO Order Actually Requires
The communication continues a directive first issued on 22 October 2025 (reference F. No. IT/ONDLS/MFG/Exp/2025/003) and operationalises the Digital Monitoring System (DMS) hosted on CDSCO’s Online National Drug Licensing System (ONDLS) portal. Under the order, as reported by Business Standard and documented by regulatory advisory firm Arogya Legal:
- Mandatory registration — every manufacturer and relevant vendor or supplier of a covered solvent must register on ONDLS. Firms already holding a manufacturing licence must register and file their data through the “Old Licence Management” facility.
- Batch-wise data upload — for each batch, the DMS requires total quantities manufactured, batch-wise manufacturing and supply data, Certificates of Analysis (CoA), quantities supplied, vendor credentials and complete onward distribution records.
- System-generated NOC before distribution — the 27 October order states plainly that no batch of a covered pharmaceutical-grade solvent “should be distributed without uploading the required details sought on the DMS and obtaining system generated no-objection certificate.”
- Enforcement via states — State and UT Drug Controllers are directed to ensure compliance across all manufacturing and supply units in their jurisdiction, with high priority attached to the rollout.
🧪 The Ten Solvent Groups Now Under Digital Tracking
The annexure to the notification lists ten categories of materials. Because these are starting materials rather than finished medicines, the list reaches upstream of the formulation factory — the layer where contamination is hardest to detect after the fact:
- Glycerin
- Propylene glycol
- Maltitol and maltitol solution
- Sorbitol and sorbitol solution
- Hydrogenated starch hydrolysate
- Polyethylene glycol (molecular weight below 1000)
- Diethylene glycol stearates
- Polyethylene glycol monomethyl ether (certain low molecular weights)
- Polysorbate 20/40/60/80, polyoxyl 15 hydroxystearate, polyoxyl 20 cetostearyl ether, polyoxyl 8 stearate, octoxynol 9 and nonoxynol 9
- Ethyl alcohol
CDSCO treats this group as high-risk for one overriding reason: several of these substances have legitimate industrial twins. Diethylene glycol (DEG) — a cheap, colourless industrial chemical used in brake fluids and paints — is structurally close enough to propylene glycol that substitution has repeatedly ended in mass poisoning. Propylene glycol is safe in regulated amounts; even a small intake of DEG can cause severe kidney injury, particularly in children.
💔 The Quality Failure This Rule Is Built On
The regulatory chain traces back to the 2025 Coldrif cough syrup deaths in Madhya Pradesh’s Chhindwara district. Coldrif was found to contain diethylene glycol beyond permissible limits. Business Standard and Pharmabiz reporting on the aftermath put the toll at 22 to 24 children — sources differ on the final count — and the episode triggered a high-level review chaired by Union Health Secretary Punya Salila Srivastava with all states and UTs.
Critically, CDSCO’s subsequent facility inspections found that several licensed drug manufacturers were not testing each batch of excipients against prescribed pharmacopoeial standards before using them in formulations. The regulator’s response came in two parts: a push for mandatory batch testing of raw materials and finished products, and this digital tracking layer at the solvent-supply stage.
📤 The Open Question: Does the NOC Rule Cover Exports?
This is where the order currently bites commercially. Industry executives told Business Standard that the directive does not distinguish between quantities intended for domestic consumption and those meant for export, and that the requirement appears to sweep in the entire supply chain — including manufacturers supplying formulations to overseas markets.
“A regulatory clarification would help avoid differing interpretations across states, as cough syrups need a Certificate of Analysis from an approved government laboratory before export,” a Delhi-based pharma executive told the paper, which reported on 3 November 2026 that CDSCO had not responded to its queries. Rishi Agrawal, co-founder and CEO of TeamLease Regtech, argued the other way: export-oriented units hold drug manufacturing licences under the Drugs and Cosmetics Act and draw solvents from the same supply chain as domestic manufacturers, so “a medicine made for an Indian patient should meet the same standard as one made for export.”
The practical risk is state-level divergence. Without a central clarification, drug controllers in different states may read the export ambit differently — a meaningful hazard for exporters whose buyers rely on predictable, uniform clearance documentation.
⚠️ Capacity Is the Bottleneck, Not the Rule
Industry broadly welcomed the traceability goal while flagging implementation capacity. Saurabh Agarwal, director and CEO of Mumbai-based HAB Pharmaceuticals and Research, said that while the notification primarily applies to solvent manufacturers and suppliers rather than formulation manufacturers, rollout “could lead to temporary supply disruptions as manufacturers complete registration and align with the new reporting requirements” — but expected these to be short-term, with stronger traceability and supply chain confidence over the longer run.
The sharper warning concerns state drug control departments, several of which are short-staffed. Batch-wise NOC issuance, if it arrives in bulk, could queue up. Smaller formulation manufacturers — limited inventories, dependence on regional solvent traders, less readiness for digital registration — are the most exposed. Larger companies hold more stock and stronger supplier networks to absorb delay. India’s cough and cold market is estimated at around ₹7,000 crore, with rural demand concentrated in Uttar Pradesh, Madhya Pradesh, Maharashtra’s Vidarbha region and Rajasthan — precisely the markets that lean hardest on small and regional manufacturers.
🔍 What This Means for Buyers and Importers of Indian Generics
For distributors, procurement teams and international buyers sourcing from India, this is a documentation change before it is a supply change. Four practical implications:
- Ask for the solvent NOC trail, not just the finished-product CoA — a compliant supplier can now show ONDLS registration and a system-generated NOC per solvent batch, plus CoAs naming the vendor.
- Expect short-term batch-dating variance — solvent allocation delays can shift a batch’s release date without any change in the tablet or syrup itself. Build a small buffer into lead times rather than treating a slip as a quality signal.
- Verify export-amble clarity in writing — until CDSCO clarifies the export scope, confirm with your Indian supplier which state drug controller’s interpretation governs their shipments.
- Treat traceability as a procurement asset — input-level tracking is exactly the evidence buyers need when defending quality in an audit or a tender. Ask your supplier to keep it in the product file.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Business Standard — “CDSCO mandates digital batchwise clearance for high-risk pharma solvents” (2 November 2026)
- Business Standard — “Pharma industry seeks clarity on CDSCO solvent order’s export ambit” (3 November 2026)
- Arogya Legal — “CDSCO strengthens digital tracking of high-risk pharmaceutical solvents through ONDLS” (27 October 2026)
- Pharmabiz — “CDSCO sets up digital monitoring system on ONDLS portal to monitor quality of high risk solvents” (October 2025)
- Economic Times Pharma — “Centre tightens oversight of high-risk solvents, mandates excipient testing” (29 October 2026)
- eHealth Magazine — “CDSCO Asks States to Enforce Batch Testing of Raw Materials, Excipients and Finished Drugs” (27 October 2026)
For more information, contact IMSDA at contact@indiamedicine.org.